Can you tell us about Organon’s evolution and where it stands today?
Organon is a company founded with a vision to create a healthier, better life for every woman, every day. We are one of the few pharmaceutical companies with women’s health at the core of our mission. Our commitment drives us to actively broaden the traditional definition of women’s health — moving decisively beyond reproductive health to encompass the myriad conditions that exclusively or disproportionately impact women or affect them in uniquely gender-specific ways.This forward-looking approach is what propels Organon to challenge long-standing perspectives and address the often-overlooked underserved needs within healthcare.
This commitment is particularly vital given the current landscape: a mere 4% of all healthcare investment is directed solely towards women.As a direct consequence of lack of investment women’s health remains a neglected area. Substantial knowledge gaps exist around how diseases uniquely manifest in women. This limits our comprehensive understanding of gender-specific disease progression and impedes the development of optimal, tailored treatment approaches. Organon is dedicated to addressing this inequity, fostering the research and development necessary to advance women’s health and ensure equitable care. This year marks Organon’s fourth anniversary, and the journey so far has been nothing less than exciting.
How does India factor into Organon’s global and APAC strategy?
India forms a key pillar of Organon’s global and Asia-Pacific strategy — both in terms of market potential and strategic capability. With a large and growing population, increasing healthcare awareness, and a significant unmet need in women’s health, India represents a vital growth opportunity for Organon. Our mission is to deliver impactful health solutions for women resonates strongly here, where access and education around reproductive health, maternal care, and non-communicable diseases continue to evolve.
In India, we are actively expanding partnerships with stakeholders across the healthcare continuum — from government and NGOs to private providers — to co-create sustainable impact. In many ways, India offers a blueprint for addressing health inequities at scale. What we build and learn here often informs our approach across other emerging markets in APAC and beyond.
As we move forward, India will continue to be both a growth engine and a center of excellence for Organon’s long-term vision of creating a better and healthier every day for every woman.
What are the biggest challenges facing women’s health in India?
In the last few decades, India has made significant strides in the area of family planning and reproductive health. The policies and programs of the Indian Government have been highly inclusive and progressive. In 2023, the country successfully stabilized the total fertility rate (TFR) at a replacement level of 2, a point below the replacement rate that reflected in the NFHS 5 data.
Women’s health in India is shaped by a complex interplay of medical, social, and systemic challenges. One of the persistent gaps exist in access to quality reproductive and maternal healthcare, especially in underserved and rural areas. While we’ve made progress in reducing maternal mortality, access to contraception, safe delivery, and postnatal care remains uneven.
Another major challenge is the lack of awareness and early diagnosis, particularly around conditions like polycystic ovarian syndrome (PCOS), endometriosis, osteoporosis, and even cardiovascular diseases — which often present differently in women. These are frequently overlooked or normalized due to social stigma and low health-seeking behaviour.
At Organon, we believe that tackling these issues requires a multi-stakeholder approach — empowering women with information, improving access, building capacity among healthcare providers, and driving policy dialogue. Only then can we hope to close the health equity gap and truly prioritize women’s health in India.
How is Organon leveraging digital tools to bridge these gaps?
At Organon, we are harnessing the digital technology to improve operational efficiency, enhance patient care, and expand our reach, particularly to remote parts of the country.
In last four years, we have built our internal systems based on latest technology to bring efficiencies in our operations. This have adopted technology for greater collaboration across geographies – supply chain, finance, compliance are just some examples.
During the COVID lockdown phase we adopted the training of implant for HCPs from classroom to online virtual training format. This is an important step because training and retraining is a constant requirement, and it enables us to reach doctors in remote parts of the country efficiently.
Our innovative digital platform, Organon Pro, connects us directly with doctors and healthcare providers. This platform facilitates seamless communication, provides access to valuable resources, and fosters stronger partnerships to improve patient outcomes. Organon Pro provides technical information on our products to HCP, also has clinical and counselling material available. This is our way of empowering doctors with the latest information on our products without having to depend on search engines.
We believe the prescribers of new generation and future will outgrow the traditional sales approaches. They will depend on technology to interface with manufactures and also learn about latest products. Therefore, to optimize on sales efficiencies, we have online digital campaigns using emails, WhatsApp and other platforms for reach our HCPs in a hassle-free way.
Advanced data analytics inform our strategic planning, allowing us to anticipate market trends and allocate resources effectively. This data-driven approach optimizes our operations and ensures we’re meeting the evolving needs of patients and healthcare providers.
Organon is committed to embracing the digital transformation and contributing to a more accessible and equitable healthcare landscape. We recognise the importance of ease of doing business in a rapidly evolving digital environment and are continuously adapting to meet the needs of patients, HCPs, and the communities we serve. We believe that by harnessing the power of digital technology, we can create a healthier future for all.
What are your long-term goals for Organon in India over the next 5–10 years?
Our vision is clear: We want to reach millions of Indian women with our medicines and improve the health of women through all stages of her life. Our focus is on conditions that are unique to women, conditions that affect her disproportionately or impact her differently, including fertility and contraception, maternal health conditions, and vaginal health. Our efforts are focussed towards:
-
Bringing innovations and more products from our global pipeline.
-
Scaling public-private partnerships.
-
Driving affordability through responsible pricing and potential insurance collaborations.
-
Supporting India’s broader healthcare goals—especially in reducing maternal mortality and improving family planning.
We expect India’s women’s health market to grow at around 8 per cent CAGR over the next six years. With the right partnerships and continued government support, we’re confident we can play a transformative role in that journey.
For me, it’s the idea that we’re making women healthier and happier—every day. It’s a philosophy that guides everything we do. Whether we’re training a doctor, introducing a new product, or designing an app, the question we ask is: Will this make life better for women?